Human immunodeficiency virus type 1 (HIV-1) resistant to the nonnucleoside reverse transcriptase inhibitor nevirapine and to the nucleoside analogue zidovudine was transmitted from a homosexual man to his sex partner. The virus source patient had commenced combination zidovudine and nevirapine therapy 2.5 years prior to his partner's primary HIV infection. He received both therapies for 7 months, then discontinued nevirapine treatment, continuing to receive zidovudine monotherapy for a further 16 months. He had ceased zidovudine therapy 6 months before the time of his partner's seroconversion. Analysis of major and minor isolates obtained from both patients soon after onset of the recipient's primary HIV infection illness confirmed that an HIV-1 variant mutant at codons 70, 98, and 181 of the viral reverse transcriptase was transmitted. This is the first documented case of transmission of HIV-1 resistant to two antiretroviral compounds.
logues and for nonnucleoside reverse transcriptase inhibitors
The following month, he enrolled in a clinical trial evaluating nevirapine and zidovudine alternating and concurrent combination including the dipyridodiazepinone, nevirapine (reviewed in strategies [7] . Patient D received combination zidovudine (600 [4] ). Substitution of cysteine for tyrosine at codon 181 is most mg/day) and nevirapine (50 mg/day, increasing to 200 mg/day at commonly observed in nevirapine monotherapy, although vari- 103, 106, 108, 188, and 190 have also been isolated from Patient D continued both therapies for 7 months, then disconpatients receiving nevirapine alone or in combination with other tinued nevirapine treatment. He continued to receive zidovudine antiretroviral compounds [4, 5] .
for a further 16 months, with variable compliance, and had ceased Zidovudine-resistant variants of HIV-1 may be transmitted all therapy for 6 months by the time his sex partner seroconverted sexually [6] , but to date, transmission of HIV-1 resistant to 14 with the appearance of a band at p24; prior to this, patient R * Other study group members are listed after text.
was HIV-seronegative. Three weeks after onset of symptoms, HIV only. Arginine was detected at codon 103 instead of lysine, the Virus isolation and drug susceptibility assays. Blood samples amino acid normally seen at this position. Since a K103N mutation were collected from patients D and R soon after onset of symptoms is normally associated with resistance to the nonnucleoside reverse of patient R's primary HIV infection illness. Peripheral blood motranscriptase inhibitors, the significance of the K103R substitution nonuclear cells (PBMC) were obtained by ficoll-hypaque density is not known. These data are summarized in table 1 and figure 1. gradient centrifugation and cocultured with phytohemagglutinin Patient R. Isolates obtained from the seroconverter 21, 35, (PHA)-stimulated seronegative donor PBMC in RPMI 1640 meand 84 days following onset of his acute illness were resistant to dium supplemented with 10% (vol/vol) fetal calf serum, interleunevirapine. The earliest isolate was highly resistant, with an IC 50 kin-2, glutamine, and antibiotics (R-10 medium). Half of the me-ú10 mM. The isolates obtained at days 35 and 84 continued to dium was exchanged every 3 or 4 days and fresh PHA-stimulated demonstrate the nevirapine-resistant phenotype, but to a lesser donor PBMC were added weekly. Virus production was monitored extent (IC 50 , 2.1 and 1.13 mM, respectively). Although the predomby p24 antigen ELISA (Coulter, Hialeah, FL). HIV p24-positive inant isolate in the virus donor, patient D, was phenotypically supernatants were used to generate virus stocks as previously deresistant to zidovudine (IC 50 , 1.1 mM), the earliest isolate obtained scribed [6, 7] . Stocks were titrated and assayed for zidovudine and from patient R was more sensitive to zidovudine, with an IC 50 of nevirapine susceptibility as previously described [6, 7] . 0.2 mM. Although the K70R mutation was detected in the day 35 Generation of biologic clones. Patient PBMC were cocultured isolate, the zidovudine IC 50 was 0.09 mM, indicating a sensitive with PHA-stimulated seronegative donor cells under limiting diluphenotype. By day 84, however, HIV-1 with a zidovudine-resistant tion conditions [8] , and positive cultures were expanded into virus phenotype (0.54 mM) was isolated. Clones isolated at day 21 and stocks.
day 35 were resistant to nevirapine (range, 1.35-2.6 mM) and were Extraction of viral RNA and generation of cDNA. Viral RNA susceptible to zidovudine (range, 0.01-0.14 mM). These data are was extracted from low-passage, p24-positive culture supernatant, summarized in table 1. and cDNA was prepared as previously described [6, 7] .
The isolate obtained from patient R 21 days after onset of sympSequencing of the reverse transcriptase gene. The viral reverse toms of primary HIV infection illness was mutant at codon 181 transcriptase gene was amplified with the primers RT01 (5-GTA-(YjC); the K70R mutation was also detected as a minor popula-GAATTCTGTTGAGTCAGATTGG-3) and RT02 (5-GATtion. At day 35, the major species was mutant at codons 70 (KjR), AAGGTTGGGCCTTATCTATTCCAT-3) in a first-round poly-98 (AjG), and 181 (YjC). Minor species isolated at days 21 merase chain reaction (PCR). The reaction proceeded for 35 cycles and 35 were mutant at codons 70 (KjR) and 181 (YjC) and (95ЊC for 1 min, 55ЊC for 2 min, 75ЊC for 3 min, with a further at codons 98(AjG) and 181 (YjC). Eighty-four days after onset 10-min extension interval at 75ЊC) in 50 mM TRIS-HCl, pH 8.3, of symptoms and 60 days after commencing zidovudine treatment, 30 mM KCl, 1.5 mM MgCl 2 , and 1.0 mM each dNTP. In a second, the zidovudine resistance marker mutation at codon 215 (TjY) nested reaction, a 768-bp segment of DNA encompassing the cowas detected in addition to mutations at positions 70 (KjR) and dons associated with zidovudine and nevirapine resistance was 181 (YjC). amplified, with the primers A (5-TTCCCATTAGCCCTATT-3)
As with patient D, a K-to-R substitution was seen at codon 103 and NE1 (5-TCATTGACAGTCCAGCT-3). The reaction proin all patient R isolates analyzed. The significance of this change, ceeded for 30 cycles (95ЊC for 1 min, 45ЊC for 1 min, 75ЊC for with respect to alterations in drug susceptibility, needs to be investi-1 min) in the reaction mixture used previously. PCR products gated further. These data are summarized in table 1 and figure 1. were purified with the Wizard DNA purification system (Promega, Madison, WI) and sequenced by use of the PRISM sequencing kit (Applied Biosystems, Foster City, CA).
Discussion
We have identified a case of transmission of HIV-1 resistant resistance to these compounds were isolated from patient D large number of replicative events accompanying the acute phase and the concurrent zidovudine selection pressure. Alterwithin 35 days of onset of symptoms of his partner's primary infection illness. The recipient, patient R, commenced zidovudnatively, resistant variants mutant at codon 215 may have been transmitted and rapidly predominated under the selective presine monotherapy 14 days after onset of symptoms of his primary HIV infection illness. Analysis of sequential isolates sure of patient R's zidovudine treatment, despite the fact that we did not detect codon 215 mutants in patient D's isolates. showed that HIV-1 with the K70R, T215Y, and Y181C genotype predominated at day 84, replacing the Y181C genotype
The major species isolated from patient D was resistant to nevirapine and zidovudine. We did not detect zidovudine resisthat predominated soon after infection.
Although mutations associated with nevirapine resistance tance -conferring mutations in patient D's isolates other than the K70R mutation as a mixed population, suggesting that have been observed in isolates obtained from nonnucleoside reverse transcriptase inhibitor -naive patients [9] , they occur minor variants mutant at one or more of the substitutions associated with zidovudine resistance, particularly codon 215, may at low frequency in normal conditions, and it may be assumed that these substitutions do not confer a survival advantage in have been present but were not identified. It is possible that these variants would be selected and amplified in the course the absence of drug. The continued presence of HIV-1 with reduced sensitivity to nevirapine almost 2 years after patient of the susceptibility assay, when virus is isolated in the presence of zidovudine, producing the resistant phenotype. D stopped taking the drug was surprising. Nevirapine-resistant mutants also predominated in our patient R soon after transmis-
The clinical consequences of primary infection with drugresistant virus have not been established. In a recent study that sion. In addition, Richman et al. [5] were able to isolate nevirapine-resistant HIV-1 from 3 patients at least 14 weeks after compared seroconverters infected with zidovudine-resistant HIV-1 and patients infected with wild type virus, we found no withdrawal of therapy. These data suggest that certain drugresistant viruses may possess a survival advantage compared difference in either CD4 cell count 1 year after infection or duration of primary infection illness [6] . Differences in clinical with the wild type form, even when drug selection pressure has been removed. Persistence of resistance-conferring mutaoutcomes may become apparent after a longer period of observation, although studies that are able to enroll a greater number tions after cessation of therapy has also been described in patients who received long-term zidovudine treatment [10] , and of patients will be able to address this question most accurately. When patients are infected with zidovudine-resistant virus, we have recently shown that transmitted zidovudine-resistant viruses may persist for up to 1 year following transmission or the clinical benefit of zidovudine therapy for primary HIV infection is unclear. In addition to our patient R, a number may revert to the wild type genotype and phenotype [6] .
The appearance of zidovudine-resistant HIV-1 mutant at coof patients infected with zidovudine-resistant virus have been treated with drug [6, 11, 12] . Although it may be postulated don 215 within 3 months of primary infection suggests that the T215Y mutation emerged rapidly as a consequence of the that administration of zidovudine during the acute phase could / 9d2a$$ju22 04-25-97 11:39:14 jinfa UC: J Infect result in rapid selective outgrowth of resistant viruses and an tion to drug resistance investigations, are necessary before any firm conclusions can be reached. increased virus burden, no clear association was found between primary infection with resistant virus, zidovudine therapy, and Primary infection with drug-resistant HIV-1 can be expected to occur more often as more antiretroviral compounds become disease progression in the limited number of cases described. been treated with antiretroviral agents and who are assumed to be infected with susceptible virus may in reality harbor
